The CoVIg-19 Plasma Alliance confirmed that patients are being enrolled in the Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) phase III clinical trial sponsored by NIAID, part of the NIH. The trial will evaluate the safety, tolerability and efficacy of an investigational anti-coronavirus hyperimmune intravenous immunoglobulin (H-Ig) medicine for treating hospitalized adults at risk for serious complications of COVID-19 disease. If successful, it may become one of the earliest treatment options for hospitalized COVID-19 patients. Like the entire global population, Yourway is paying close attention to the development of more effective therapeutics for COVID-19 and ready to support these efforts regardless of urgency.